Clinical trial
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes…
NCT00461058 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00461058 |
|---|---|
| Title | A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure. |
| Official title | A Randomized, Double Blind Study to Compare the Safety and Tolerability of Aleglitazar and Actos in Patients With Type 2 Diabetes and NYHA Class II Heart Failure. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | Actos, aleglitazar |
| Enrollment | 14 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 17, 2007 |
| Last update posted | Aug 5, 2016 |
| Countries | Israel, Mexico, Romania, Russia, Ukraine, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: